Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Acta Diabetologica
Erschienen in: Acta Diabetologica 3/2019

21.09.2018 | Review Article

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

verfasst von: Juan Ling, Peng Cheng, Long Ge, Ding-hua Zhang, An-chen Shi, Jin-hui Tian, Ya-jing Chen, Xiu-xia Li, Jing-yun Zhang, Ke-hu Yang

Erschienen in: Acta Diabetologica | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes.

Methods

We searched the Cochrane Library, PubMed, EMBASE, Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), and the Wanfang Database from inception to April, 2018. Randomized controlled trials were included if they compared the different versions of DPP4-I with each other or with placebo in treatment of type 2 diabetes. Bayesian network meta-analysis and pairwise meta-analysis were performed to evaluate the efficacy and safety of the different kinds of DPP4-I and placebo. The data were analyzed using STATA 12.0 and WinBUGS1.4 software.

Results

We identified 58 eligible studies (with 31356 patients) involving 14 treatment arms. Indirect comparison results showed that except for alogliptin, a decrease was found for all DPP4-I versus the placebo for hemoglobin A1c (HbA1c) with vildagliptin50 twice daily (BID) showing the highest probability. Linagliptin5 once daily (QD) decreased the level of fasting plasma glucose (FPG) the most for all DPP4-I versus the placebo; when comparing them with each other, alogliptin25QD was more effective when compared with sitagliptin100QD and vildaglipti50BID; linagliptin5qd had the highest decrease impact on body mass index (BMI). Except for hypoglycemia and upper respiratory tract infection (URTI), there are no statistical significance on incidence of adverse events and the body weight when DPP4-I are compared with each other or with placebo.

Conclusion

Our network meta-analysis presents the associations of DPP4-I versus placebos on HbA1c, FPG, 2 h postprandial blood glucose (2HPPG), BMI, body weight and adverse events. DPP4-I have a lowering effect on the glycemic level (HbA1c, FPG), especially vildaglipti50BID and linagliptin10QD, respectively. Besides, linagliptin5QD has the greatest probabilities of reducing BMI. In addition, DPP4-I were associated with not increasing the incidence of adverse events. Among them, vildagliptin100QD and sitagliptin100QD have the lowest probability in reducing the incidence of hypoglycemia and URTI, respectively.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
3.
Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:17–18CrossRef
4.
Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663–1670PubMedCrossRef
5.
Thornberry NA, Weber AE (2007) Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 7:557–568PubMedCrossRef
6.
Tahrani AA, Piya MK, Barnett AH (2009) Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 26:249–262PubMedCrossRef
7.
Ckhardt ME, Angkop EL, Mark M et al (2007) 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl) methyl]-3, 7-dihydro-1H-purine-2, 6-dione a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type-2 diabetes. Med Chem 50:6450–6453CrossRef
8.
Feng J, Zhang ZY, Wallace MB (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. Med Chem 50:2297–2300CrossRef
9.
Gerrald KR, Van SE, Wines RC et al (2012) Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 14(6):481–492PubMedCrossRef
10.
Wan LY, Zhang C, Guo WH et al (2013) Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus: a meta-analysis. Advers Drug React J 15(6):306–313
11.
Ying L, Yu MZ, Xu XZ et al (2015) Efficacy and safety of linagliptin for type 2 diabetes mellitus: a meta-analysis. Chin J Evid Based Med 15(9):1068–1077
12.
13.
14.
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedPubMedCentralCrossRef
15.
16.
Higgins JP, Altman DG (2008) Assessing risk of bias in included studies[M]/Cochrane handbook for systematic reviews of interventions: Cochrane book series. John Wiley, Hoboken, pp 187–241CrossRef
17.
Dersimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105PubMedCrossRef
18.
Hartung J, Knapp G (2001) A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 20:3875–3889PubMedCrossRef
19.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
20.
21.
22.
Valkenhoef GV, Kuiper J (2016) Network meta-analysis using bayesian methods[M]/evidence synthesis for decision making in healthcare. John Wiley, Hoboken, pp 76–93
23.
Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRef
24.
Dias S, Sutton AJ, Ades AE et al (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Med Decis Making 33:607–617PubMedPubMedCentralCrossRef
25.
Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Stat Sci 7:457–472CrossRef
26.
Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163–171PubMedCrossRef
27.
Donegan S, Williamson P, D’Alessandro U, Tudur-Smith C (2013) Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods 4:291–323PubMedCrossRef
28.
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity an fit. J R Stat Soc Ser B (Stat Methodol) 64:583–639CrossRef
29.
Tian JH, Zhang J, Ge L, Yang KH, Song FJ (2017) The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol 85:50–58PubMedCrossRef
30.
Xiaoyan C, Jing W, Xiaochun H, Yuyu T, Shunyou D, Yingyu F (2016) Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Curr Med Res Opin 6:1–6
31.
Koyanagawa N, Miyoshi H, Ono K et al (2016) Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. Endocr J 63(8):747PubMedCrossRef
32.
Asti A, D’Alessandro A, Zito FP et al (2016) Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients. Italian J Med 10(1):36CrossRef
33.
Huang HH, Xu WQ et al (2015) Comparative study on the efficacy of saxagliptin and vildagliptin in treating type 2 diabetes mellitus. Jiangxi Med J 2015(9):859–860
34.
Chen P (2015) Clinical efficacy of DPP-IV inhibitor combined with metformin on type 2 diabetes mellitus. North Pharmaceutical (9):88–89
35.
Tang YZ, Wang G, Jiang ZH et al (2015) Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetol Metab Syndrome 7(1):91CrossRef
36.
Kothny W, Lukashevich V, Foley JE et al (2015) Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia 58(9):2020–2026PubMedPubMedCentralCrossRef
37.
Göke R, Eschenbach P, Dütting ED (2015) Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: results of a randomized controlled trial. Diabetes Metabol 41(3):244–247CrossRef
38.
Li LY, He X, Xie M et al (2014) Comparative study on the efficacy of Sitagliptin and saxagliptin in treating type 2 diabetes mellitus. 14(6):11–12.
39.
Takihata M, Nakamura A, Terauchi Y et al (2014) Comparative study of three DPP-4 inhibitors, namely sitagliptin, vildagliptin, and alogliptin, in Japanese type 2 diabetic patients: the cosva randomized, controlled trial. Clin Diabetes Ther Posters 106:1024
40.
Li CJ, Yu Q, Yu P et al (2014) Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes 122(8):469PubMedCrossRef
41.
Sakamoto M, Nishimura R, Irako T et al (2012) Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 11(1):92PubMedPubMedCentralCrossRef
42.
Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Pathophysiol Complicat 35(10):2076–2082
43.
Guerci B, Monnier L, Serusclat P et al (2012) Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized optima study. Diabetes Metab 38(4):359–366PubMedCrossRef
44.
Wang W, Yang J, Yang G et al (2016) Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J Diabetes 8(2):229PubMedCrossRef
45.
Yang W, Xing X, Lv X et al (2015) Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J Diabetes 7(2):174PubMedCrossRef
46.
Sheu WHH, Park SW, Yan G et al (2015) Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Curr Med Res Opin 31(3):1–34CrossRef
47.
Schmieder RE, Friedrich S, Kistner I et al (2015) Effects of linagliptin on early alterations of renal endothelial function in patients with type-2 diabetes. Nephrol Dial Transplant 30(suppl_3):iii11CrossRef
48.
Chantal M, Ravi SR, Daniel L et al (2015) A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther 6(2):127CrossRef
49.
Leibowitz G, Cahn A, Bhatt DL et al (2015) Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab 17(5):487PubMedCrossRef
50.
Laakso M, Rosenstock J, Groop PH et al (2015) Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care 38(2):15–17CrossRef
51.
Kohei K, Takashi K, Yasuo T et al (2015) Sitagliptin improves glycemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 17:11
52.
Wu YF (2013) The effect of saxagliptin monotherapy on treating new type 2 diabetes. Doctoral dissertation, Zhejiang University
53.
Yang W, Guan Y, Yue S et al (2012) The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 4(3):227–237PubMedCrossRef
54.
Rauch T, Graefe-Mody U, Deacon CF et al (2012) Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 3(1):10PubMedPubMedCentralCrossRef
55.
Pan CY, Yang W, Tou C et al (2011) Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 28(3):217–224
56.
Pan C, Xing X, Han P et al (2012) Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 14(8):737–744PubMedCrossRef
57.
Minervini G, Iqbal N, Charbonnel B et al (2012) Efficacy and safety of saxagliptin in combination with insulin in patients with long-standing type 2 diabetes. Intern Med J 61:A290
58.
Kothny W, Shao Q, Groop P et al (2012) One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 14(11):1032–1039PubMedCrossRef
59.
Kawamori R, Inagaki N, Araki E et al (2011) Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 14(4):348–357CrossRef
60.
Gerosa D, Ragonesi PD, Anna C et al (2012) Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother 13(18):2581–2591CrossRef
61.
Derosa G, Carbone A, Franzetti I et al (2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 98(1):51–60PubMedCrossRef
62.
Barnett A, Huisman H, Jones R et al (2012) Efficacy and safety of linagliptin in elderly patients (≥ 70 Years) with type 2 diabetes. Can J Diabetes 36(5):S39CrossRef
63.
Tajima N, Kadowaki T, Odawara M et al (2011) Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int 2(1):32–44CrossRef
64.
Seino Y, Fujita T, Hiroi S et al (2011) Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 27(9):1781–1792PubMedCrossRef
65.
Del PS, Barnett AH, Huisman H et al (2011) Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13(3):258CrossRef
66.
Nowicki M, Rychlik I, Haller H et al (2011) Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 13(6):523PubMedCrossRef
67.
Nowicki M, Rychlik I, Haller H et al (2011) Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 65(12):1230PubMedCrossRef
68.
Mcgill JB, Sloan L, Newman J et al (2013) Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. A 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 36(2):237CrossRefPubMedPubMedCentral
69.
Lukashevich V, Schweizer A, Shao Q et al (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13(10):947–954PubMedCrossRef
70.
Lukashevich V, Schweizer A, Foley J, Shao Q, Groop PH, Kothny W et al (2011) Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment. Diabetologia 54(Suppl1):S332
71.
Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukashevich V et al (2011) Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia. 54(Suppl1):S332
72.
Newman J, Mcgill JB, Patel S, Friedrich C, Sauce C, Woerle HJ et al (2011) Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia 54(Suppl1):S333
73.
Horie Y, Kanada S, Watada H et al (2011) Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 33(7):973PubMedCrossRef
74.
Dandona P, Makdissi A, Chang S et al (2011) Sitagliptin exerts an anti-inflammatory effect. Am Diabetes Assoc 60:A306
75.
Barzilai N, Guo H, Mahoney EM et al (2011) Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 27(5):1049–1058PubMedCrossRef
76.
Garber AJ, Foley JE, Banerji MA et al (2010) Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10(11):1047–1056CrossRef
77.
Defronzo RA, Fleck PR, Wilson CA et al (2008) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31(12):2315–2317PubMedPubMedCentralCrossRef
78.
Chan JC, Scott R, Arjona Ferreira JC et al (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10(7):545–555PubMedCrossRef
79.
Su Y, Lv LF, Li QZ, Zhao ZG (2014) A randomized controlled clinical trials for the treatment of type 2 diabetes by vildagliptin and alpha-glucosidase inhibitor. Chin J New Drugs 22:2655–2658
80.
Lukashevich V, Kozlovski P, Foley J, Kothny W et al (2012) Vildagliptin combined with insulin reduces HBA1C without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Diabetes 61:A254
81.
Moses RG, Kalra S, Brook D, Sockler J, Visvanathan J, Fisher SA (2012) Saxagliptin (SAXA) effectively reduces HbA1c and is well tolerated when added to a combination of metformin (MET) and sulfonylurea (SU). Clin Diabetes/Ther Posters 61:A282
82.
Su Y, Lv LF, Li QZ, Zhao ZG, Su YL (2014) The clinical research on the treatment of type 2 diabetes mellitus by DPP-4 inhibitor. Chin J Diabetes 22(10):886–889
83.
Ba J, Han P, Yuan G et al (2017) Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes 09:667–676CrossRef
84.
Pan C, Han P, Ji Q, li C, Lu J et al (2017) Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: a multicentre randomized double-blind placebo-controlled phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes 09:386–395CrossRef
85.
Shah A, Levesque K, Pierini E et al (2017) Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. Diabetes Obes Metab 20:1–6
86.
Tanaka K, Okada Y, Mori H et al (2017) Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocr J 64(2):179–189PubMedCrossRef
87.
Wang W, Ning G, Ma J et al (2017) A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. Curr Med Res Opin 33(4):693–699PubMedCrossRef
88.
Sun F, Wu S, Guo S et al (2015) Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48(3):794–803PubMedCrossRef
89.
Sun F, Wu S, Guo S et al (2015) Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 10(1):26–37CrossRef
90.
Jansen JP, Fleurence R, Devine B et al (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health 14(4):417–428PubMedCrossRef
91.
Cai L, Cai Y, Lu ZJ et al (2012) The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 37(4):386PubMedCrossRef
92.
Bekiari E, Rizava C, Athanasiadou E et al (2015) Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine 52(3):458–480PubMedCrossRef
93.
Singhfranco D, Mclaughlinmiddlekauff J, Elrod S et al (2012) The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 14(8):694–708CrossRef
94.
Bryzinski BHB (2015) A pooled analysis of the efficacy and safety of saxagliptin as monotherapy in patients with type 2 diabetes. J Diabetes Metab 06:4
95.
Shin S-J (2012) Glucagon-like peptide-1 receptor agonists and their effects on weight reduction. J Diabetes Investig 03:490–491CrossRef
96.
Resnick HE, Valsania P, Halter JB et al (2000) Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Commun Health 54(8):596–602CrossRef
97.
Ford ES, Williamson DF, Liu S (1997) Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 146:214–222PubMedCrossRef
98.
Moghissi E, Ismailbeigi F, Devine RC (2013) Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr Pract 19(3):1–33CrossRef
99.
Mbanya JC, Al-Sifri S, Abdel-Rahim A et al (2015) Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract 109(2):226–232PubMedCrossRef
100.
Kim HM, Lim JS, Lee BW et al (2015) Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. Endocrinol Metab 30(1):84–91CrossRef
101.
Phung OJ, Scholle JM, Talwar M et al (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain and hypoglycemia in Type 2 diabetes. JAMA 303(14):1410–1418PubMedCrossRef
102.
Zhao Q, Hong D, Zheng D et al (2014) Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug Des Dev Ther 8:2283
103.
Bhattacharjee A, Gupta MC, Agrawal S (2016) Adverse drug reaction monitoring of newer oral anti-diabetic drugs—a pharmacovigilance perspective. Int J Pharmacol Res 6(04):142–151
104.
Esposito K, Chiodini P, Maiorino MI et al (2014) Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open 4(6):e005442–e005442PubMedPubMedCentralCrossRef
105.
Karagiannis T, Paschos P, Paletas K et al (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:449–449CrossRef
106.
Caldwell DM, Ades AE, Higgins JPT (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897–900PubMedPubMedCentralCrossRef
Metadaten
Titel
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
verfasst von
Juan Ling
Peng Cheng
Long Ge
Ding-hua Zhang
An-chen Shi
Jin-hui Tian
Ya-jing Chen
Xiu-xia Li
Jing-yun Zhang
Ke-hu Yang
Publikationsdatum
21.09.2018
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 3/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1222-z

Weitere Artikel der Ausgabe 3/2019

Acta Diabetologica 3/2019 Zur Ausgabe

Original Article

Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young

Original Article

High intensity interval training protects the heart during increased metabolic demand in patients with type 2 diabetes: a randomised controlled trial

Short Communication

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Letter to the Editor

Serum bilirubin concentrations, type 2 diabetes and incident coronary heart disease

Original Article

Transient neonatal diabetes mellitus and hypomethylation at additional imprinted loci: novel ZFP57 mutation and review on the literature

Original Article

Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise